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Strange Trips: Science, Culture, and the Regulation of Drugs by Lucas Richert 
Abstract 
In Strange Trips: Science, Culture, and the Regulation of Drugs, Lucas Richert sets out to “investigate the 
myths, meanings and boundaries of certain recreational drugs and pharmaceuticals,” a goal motivated by 
the call to “move beyond examining substances in silos” and “put drugs in conversation with each other.” 
The book’s theme is bolstered by wide-ranging and thorough research across such diverse media as 
medical journals, political speeches, pop culture, and news reports, with an investigative dive showcasing 
Richert’s expertise as a historian of pharmacology. Strange Trips’ ambitious scope—from the use of 
heroin as an end-of-life painkiller to the American public’s obsession with weight loss and the diet 
pills—sets the stage for a broad discussion as to the role and meaning of drug use and abuse in the North 
American context. Ultimately, Strange Trips serves as an excellent introductory text to the socio-political 
dimensions of drug regulation in Canada and the United States and is a readable resource for anyone 
interested in the politics of drug regulation. 










Strange Trips: Science, Culture, and the 
Regulation of Drugs by Lucas Richert1 
IRMAK AYDEMIR2 
In Strange Trips: Science, Culture, and the Regulation of Drugs, Lucas Richert sets 
out to “investigate the myths, meanings and boundaries of certain recreational 
drugs and pharmaceuticals,” a goal motivated by the call to “move beyond 
examining substances in silos” and “put drugs in conversation with each other.”3 
Te book’s theme is bolstered by wide-ranging and thorough research across 
such diverse media as medical journals, political speeches, pop culture, and news 
reports, with an investigative dive showcasing Richert’s expertise as a historian 
of pharmacology. Strange Trips’ ambitious scope—from the use of heroin as an 
end-of-life painkiller to the American public’s obsession with weight loss and 
the diet pills—sets the stage for a broad discussion as to the role and meaning 
of drug use and abuse in the North American context. Ultimately, Strange Trips
serves as an excellent introductory text to the socio-political dimensions of drug 
regulation in Canada and the United States and is a readable resource for anyone 
interested in the politics of drug regulation. 
Strange Trips’ greatest contribution to the literature on the history of 
pharmacology may be its engagement with and accessible exposition of primary 
source material. Across its three sections, Strange Trips draws on committee 
reports, scientifc journals, and press releases to illustrate the complexities 
underlying drug regulation policy and the shifting tides of public opinion. Te 
1. (McGill-Queen’s University Press, 2018). 
2. JD Candidate 2021, Osgoode Hall Law School, Toronto, Canada. 







AYDEMIR, STRANGE TRIPS 529 
result is a manuscript that moves beyond common references to drugs in popular 
culture and beyond references to “Reefer Madness, Harry J. Anslinger, or … Bob 
Marley,”4 to situate at a macroscopic level the various factors that infuence and 
mould drug policy. Unrestricted by a narrow focus on a particular decade, class 
of drugs, or country, Strange Trips’ engagement with primary sources illustrates 
the infuence of the United Kingdom’s medical community on the legislatures of 
Canada and the United States over the past century; reveals the political nature 
of drug research funding; and brings to the fore tensions between public health 
concerns and the industry of drug sales, to list but three of the book’s contributions. 
Crucially, Strange Trips is highly readable throughout: Rather than tailor the 
language of his dense research to meet the needs of an expert in the feld, Richert 
writes with an eye to the average interested reader. Strange Trips favours readily 
accessible language over technical language, a welcome decision for a text that, 
in part, describes the chemical makeup of drugs and their various medical efects. 
Richert also works to situate the unfamiliar in the well-known. For instance, 
in discussing the Food and Drug Administration’s (FDA) role in drug regulation 
during the AIDS crisis, Richert borrows from depictions of the FDA in the flm 
Dallas Buyers Club to dispel notions of the organization as a mere “cardboard 
villain” that frustrated informed patient groups that were battling for end-of-life 
relief.5 Mindful attention to audience is consistent and apparent throughout 
Strange Trips and the dense research of its contents is manageable and highly 
enjoyable to read as a result. 
For all its merits, Strange Trips nevertheless sufers from two faws that dull 
its impact. One faw is in its organization. Tough Richert’s expert research is 
presented as a unifed monograph, Strange Trips may have been better presented 
as a collection of stand-alone essays sorted under headings that signal unifying 
themes. Te book’s three Parts and several chapters make explicit reference to 
each other only rarely; connections between the trajectories of diferent drugs 
in the public, political, and medical arenas are only occasionally drawn. It’s a 
wonder why the book’s frst section on “End-of-Life Medicines” isn’t subsumed 
under Parts two or three, which discuss when drugs breach “the barrier of 
drug legitimacy” and when they “can be jolted from a position of acceptance,” 
respectively.6 Placing the frst section of the book under either of the latter two 
sections may have made greater editorial sense: In discussing the use of heroin or 
Laetrile for end-of-life relief, Richert discusses perceptions of the drugs’ benefts 
4. Ibid at 15 [emphasis in original]. 
5. Ibid at 57. 
6. Ibid at 15-16; see also ibid at 79, 121. 







and relative dangers, themes that re-emerge and feature dominantly in the two 
sections that follow and that are dedicated to such a discussion. As it stands, 
it is only upon a second read that an average reader may fnd themselves capable 
of connecting the dots between the discussion of Laetrile in chapter two and the 
exploration of obesity and the diet pill in chapter seven. Te book’s pillars, laid 
out in the introduction, do little to help navigate such substantive complexity: 
Richert efectively promises and delivers a manuscript that shows how “the 
popularity and use of drugs ebbs and fows.”7 However, contrary to the author’s 
aim, it often feels like each drug is discussed in a silo. In this sense, Strange Trips’ 
broad scope serves as a double-edged sword: It provides the beneft of breadth but 
compromises the fow of its overarching narrative. 
Within sections, chapters tackle discrete cases: heroin and Laetrile in the 
frst section; LSD and cannabin the second; and the American pharmaceutical 
industry, quick-fx diet pills, and ketamine in the fnal section. Tough 
instructive as individual works of their own, chapters are sometimes bogged 
down by transitions that are blunt and jarring. For instance, the move from the 
chapter on the American regulation of cheaper, Canadian-imported drugs to the 
chapter on diet pills is made in a single, abrupt sentence at the end of a paragraph 
summarizing the United States’ closed distribution system. Similarly, subheadings 
within chapters sometimes fail to organize chapter contents helpfully. Richert’s 
discussion of heroin, for example, briefy reviews the drug’s history in the United 
States from 1874 to the Nixon administration in the 1970s under one subheading, 
then discusses heroin advocacy and resistance under another before returning to a 
late 1980s discussion of the drug under a conclusionary subheading. 
To organize the entirety of Richert’s research chronologically would have 
surely meant a drier read; in fairness to him, the book is organized so as to avoid 
“proceed[ing] in a uniformly chronological fashion” and Richert states openly 
that the book does not “employ linear argumentation.”8 Still, sorting through the 
information contained in Strange Trips’ pages is oftentimes made difcult without 
a chronological fow, and Richert would have beneftted from drawing a greater 
number of explicit connections between and within chapters, and between and 
within sections, to truly “put drugs in conversation with one another.”9 
Te other faw dulling Strange Trips’ impact is substantive. Despite centering 
much of the debate about drugs and pharmaceuticals around the patients who 
stand to beneft from them, Richert seldom quotes from patients or activists, 
7. Ibid at 8. 
8. Ibid at 13. 
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instead expounding the views of prominent professionals and politicians. For 
instance, US Representative Steven D. Symms, who “sought to legalize Laetrile 
nationally and curtail the authority of the FDA,” is discussed as a fgure who 
“propounded a growing view that bureaucrats in the agency lacked compassion 
for patients,”10 though the patients themselves are given no space to provide their 
own views. Admittedly, Strange Trips never promises to engage extensively with 
what questions preoccupy the normative backdrop of drug regulation: Richert’s 
text is not designed to defend an argument in favour of deregulation, unobstructed 
patient autonomy, or the like, so largely omitting patient perspectives doesn’t 
detract much. In the context of its own goals, however, the scarcity of patient 
perspectives in the text is striking. Since Richert invites readers to consider 
which medicines ought to be consumed at the end of life, and whether certain 
therapies meet the needs of the dying, failing to ofer the perspectives of such 
individuals in any great detail is telling.11 Tis is not to suggest that Richert fails 
to address questions such as these throughout Strange Trips, but that he does so 
predominantly from the perspectives of medical experts, interested politicians, 
and the occasional advocacy group like the International Association of Cancer 
Victims and Friends.12 Te reader who values greatly the role of patient viewpoints 
in medical discussions is likely to fnd this feature of Strange Trips disappointing; 
the reader who prefers to refect on the viewpoints of professionals is likely to 
fnd it refreshing. 
Overall, despite an oft-confusing organizational structure and a narrative 
that prioritizes professional standpoints over patient opinions, Strange Trips
is an excellent resource for the reader looking for a thorough birds-eye view 
introduction to the politics of drug regulation. Te book is comprehensive, 
accessible, and expertly researched, as well as topical—especially in the era of 
cannabis legalization in Canada and some American states, and the opioid crisis 
in large parts of North America. Readers looking for a more argumentative stance 
should look elsewhere; those who are content to review an expert’s synthesis of 
available research should not pass on Strange Trips. 
10. Ibid at 68. 
11. Ibid at 7. 
12. See ibid at 71. 
